SCHEMBL19334205

SCHEMBL19334205

CCC(C)(C)C(=O)[C@H](COC)NC(=O)OC

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 5/20 0.35
▸ CTSS P25774 4/20 0.35
▸ CA12 O43570 1/20 0.31
▸ CA1 P00915 1/20 0.31
▸ CA2 P00918 1/20 0.31
▸ CA3 P07451 1/20 0.31
▸ CA4 P22748 1/20 0.31
▸ CA6 P23280 1/20 0.31
▸ CA5A P35218 1/20 0.31
▸ CA7 P43166 1/20 0.31
▸ CACNA1C Q13936 1/20 0.31
▸ SCN9A Q15858 1/20 0.31
▸ CA9 Q16790 1/20 0.31
▸ CA13 Q8N1Q1 1/20 0.31
▸ CA14 Q9ULX7 1/20 0.31
▸ CA5B Q9Y2D0 1/20 0.31
▸ CTSL P07711 1/20 0.31
▸ CTSB P07858 1/20 0.31
▸ CYP1A2 P05177 1/20 0.30
▸ CYP2C9 P11712 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19578133 0.87 CTSK (0.35) CTSKCTSSCA12CA1CA2
SCHEMBL19334263 0.86 CTSK (0.35) CTSKCTSSCA12CA1CA2
SCHEMBL19334169 0.86 CTSK (0.40) CTSKCTSSCA1CA2CYP1A2
SCHEMBL19578058 0.86 CTSK (0.40) CTSKCTSSCA1CA2CYP1A2
SCHEMBL19318525 0.84 CTSS (0.34) CTSKCTSSCA12CA1CA2
SCHEMBL8906249 0.84 CTSS (0.34) CTSKCTSSCA12CA1CA2
SCHEMBL19578130 0.83 CTSK (0.42) CTSKCTSSCA1CA2CTSL
SCHEMBL19578484 0.81 CTSK (0.33) CTSKCTSS
SCHEMBL19334207 0.79 SMN1; SMN2 (0.34) CTSKCTSS
SCHEMBL8916705 0.74 CA12 (0.34) CTSKCTSSCA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170320833-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-11-09 — — US disclosed
US-9758487-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-09-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170320833-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, PYGL, HCCS CTSK 789/4885CTSS 864/4885CA12 3169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback